<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00134654</url>
  </required_header>
  <id_info>
    <org_study_id>02-306</org_study_id>
    <nct_id>NCT00134654</nct_id>
  </id_info>
  <brief_title>Two Doses of Conjugated Estrogen (Premarin) in Patients With Androgen-Independent Prostate Cancer</brief_title>
  <official_title>A Phase II Trial of Two Doses of Conjugated Estrogens (Premarin) in Patients With Androgen-Independent Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lowell General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>South Shore Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Emerson Hospital, Concord, MA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Saint Anne's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if Premarin is useful against androgen-independent
      prostate cancer and to help understand how drugs such as Premarin may work.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be randomly assigned to one of two study groups (arm A or Arm B). Arm A will
      receive 1.25mg of Premarin once daily and arm B will receive 1.25mg of Premarin three times a
      day. Patients will also receive coumadin daily to help prevent thromboembolic disease.

      After reviewing the first 30 patients on Arm A, it was determined that arm A (low dose
      Premarin) was not effective. Arm A was then closed and patients on Arm A were given the
      choice to switch to Arm B.

      Treatment will continue until there is evidence of disease progression or unacceptable side
      effects.

      Every 4 weeks while receiving Premarin, a physical exam and blood work will be performed.
      Every 12 weeks a CT scan of the abdomen and pelvis and a bone scan will be performed.

      Patients will also be encouraged to undergo standard preventative breast irradiation prior to
      starting Premarin or up to 4 weeks after starting treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2003</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">July 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the efficacy of two different doses of Premarin in the treatment of patients with androgen-independent prostate cancer</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety of Premarin in this patient population</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Premarin once a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Premarin 3 times a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Premarin</intervention_name>
    <description>Group A: 1.25mg once a day Group B: 1.25mg three time a day Group A has been closed and participants have been given the option of enrolling in Group B. Treamtment can continue until disease progression or serious side effects.</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented histologic evidence of prostate cancer.

          -  Progressive androgen-independent prostate cancer as defined by the Prostate-Specific
             Antigen (PSA) Working Group after conventional androgen deprivation and antiandrogen
             withdrawal.

          -  PSA &gt; 2ng/ml and serum testosterone of &lt; 50ng/ml

          -  No history of thromboembolic disease within the prior year

          -  ECOG performance status of 0-2

          -  Creatinine &lt; 2 x upper limit of normal

          -  Bilirubin &lt; 2 x upper limit of normal

          -  AST &lt; 2 x upper limit of normal

        Exclusion Criteria:

          -  Unstable angina or change in anginal symptoms within the past 6 months.

          -  Prior therapy with estrogens or PC-SPECS.

          -  Concurrent megestrol acetate or steroid hormones

          -  Major surgery or radiation therapy within 4 weeks

          -  Strontium-89 or samarium-153 therapy within 8 weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Pomerantz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Insitute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 24, 2005</study_first_submitted>
  <study_first_submitted_qc>August 24, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2005</study_first_posted>
  <last_update_submitted>June 14, 2011</last_update_submitted>
  <last_update_submitted_qc>June 14, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 16, 2011</last_update_posted>
  <responsible_party>
    <name_title>Mark Pomerantz, MD</name_title>
    <organization>Dana-Farber Cancer Institute</organization>
  </responsible_party>
  <keyword>Androgen-independent prostate cancer</keyword>
  <keyword>Premarin</keyword>
  <keyword>conjugated estrogen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estrogens</mesh_term>
    <mesh_term>Estrogens, Conjugated (USP)</mesh_term>
    <mesh_term>Androgens</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

